The DEA has scheduled a hearing to discuss reclassifying cannabis as a Schedule III substance. This move, supported by industry leaders like the National Cannabis Roundtable, could ease restrictions and acknowledge cannabis’s medical benefits. The hearing reflects the growing scientific and public support for rescheduling.